Active Biotech AB Year-end Report, January - December 2009
February 11, 2010 08:30 (CET)
Laquinimod ― Phase III program proceeding according to plan
57-57 ― exploratory clinical trial in progress
RhuDex(TM) ― additional preclinical studies to be conducted in 2010
ANYARA ― Phase III trials proceeding according to plan
TASQ ― primary endpoint met in clinical Phase II
ISI ― project proceeding according to plan
Net sales of SEK 10.8 M (53.5)
Operating loss of SEK 219.6 M (loss: 184.6)
Loss after tax of SEK 224.0 M (loss: 181.6)
Loss per share for the period amounted to SEK 3.81 (loss: 3.66)
For further information, please contact:
Tomas Leanderson |
Göran Forsberg |
| Active Biotech AB |
CFO | (Corp. Reg. No. 556223-9227) |
Tel: +46 (0)46-19 20 44 | Box 724, 220 07 Lund |
Tel: +46 (0)46-19 20 00 | |
This report is also available at www.activebiotech.com | Fax +46 (0)46-19 11 00 |